Adalimumab is a fully human monoclonal IgG1 antibody against tumor necrosis factor that has been approved for the treatment of JIA since 2008 and is now widely recommended by experts [8,9,10]. This evidence concerns the gene TNF and juvenile idiopathic arthritis.